CCR4 and melanoma: In other conditions, this therapeutic venue has been demonstrated to be effective in pre-clinical models of aggressive tumors (188, 189) and in clinical trials with mogamulizumab, an anti-CCR4 therapeutic mAb which selectively decreased the fraction of CCR4+ TREG and associated with better clinical outcome in T cell malignancies and melanoma (190, 191).